Sa497 PERSISTENCE OF EXTRAINTESTINAL MANIFESTATIONS DESPITE TOTAL COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE; A RETROSPECTIVE COHORT STUDY

2021 ◽  
Vol 160 (6) ◽  
pp. S-523
Author(s):  
Nikitha Gangasani ◽  
Amar Vedamurthy ◽  
Ashwin Ananthakrishnan
Keyword(s):  
Ulcerative Colitis ◽  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Total Colectomy ◽  
Extraintestinal Manifestations

scholarly journals P791 Difference between paediatric Crohn’s disease and ulcerative colitis at diagnosis in Korea: results from a multicentre, registry-based, retrospective cohort study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S623-S623
Author(s):  
B H Choe ◽  
B Kang ◽  
H R Suh ◽  
E S Kim ◽  
J H Park ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Large Scale ◽  
Female Ratio ◽  
Cell Counts ◽  
Paediatric Crohn’S Disease

Abstract Background Despite its increasing incidence, large-scale data regarding the demographics and characteristics of paediatric inflammatory bowel disease (IBD) at diagnosis in Korea is scarce. We aimed to compare the differences of paediatric Crohn’s disease (CD) and ulcerative colitis (UC) at diagnosis in Korea. Methods This analysis was conducted using data from a multicentre, registry-based, retrospective cohort study conducted at five centres in Korea between 2013 and 2018. Baseline demographics, clinical characteristics, results from laboratory, endoscopic, radiologic examinations were compared between paediatric CD and UC patients who were <19 years at diagnosis. Results A total 307 patients were included in this analysis. Among them 227 patients were diagnosed with CD (73.9%), and 80 patients (26.1%) with UC. The male to female ratio was 2.49:1 for CD, and 1.29:1 for UC (p = 0.019). Median age at diagnosis was 14.4 years (IQR 12.4–16.2) for CD, and 14.4 (11.7–16.5) for UC (p = 0.962). Symptoms at presentation that were dominant in CD patients compared with UC patients were abdominal pain (76.2% vs. 51.2%, p < 0.001), weight loss (51.5% vs. 22.5%, p < 0.001), perianal fistulas (18.9% vs. 0%, p < 0.001), perianal skin tags (15.9% vs. 1.2%, p < 0.001), fever (20.3% vs. 6.2%, p = 0.007), and oral ulcers (13.7% vs. 3.8%, p = 0.026), while hematochezia was the only dominant symptom in UC patients compared with CD patients (86.2% vs. 30.8%, p < 0.001). White blood cell counts, platelet counts, ESR, CRP were significantly higher, and serum albumin level was significantly lower in CD patients. ASCA was positive in 44.5% and 16.2% of CD and UC patients, respectively (p < 0.001), and ANCA was positive in 15.0% and 58.8% of CD and UC patients, respectively (p < 0.001). Terminal ileal involvement on endoscopy was prominent in CD (62.1% vs. 16.2%, p < 0.001), while rectal involvement was more prominent in UC (52.4% vs. 83.8%, p < 0.001). Small bowel involvement and perianal perforating diseases on radiologic exams were also more prominent in CD. Conclusion Clinical symptoms, laboratory test results, radiologic findings, endoscopic findings were significantly different between paediatric Crohn’s disease and ulcerative colitis at diagnosis in Korea. A large-scale study on a nationwide basis is expected to better clarify this difference in the future.

scholarly journals Influence of Vitamin D3 Supplementation on Infliximab Effectiveness in Chinese Patients With Crohn's Disease: A Retrospective Cohort Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Sheng-long Xia ◽  
Quan-jia Min ◽  
Xiao-xiao Shao ◽  
Dao-po Lin ◽  
Guo-long Ma ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Vitamin D3 ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Remission Rate ◽  
Serum Cytokine ◽  
Cytokine Profiles ◽  
Tnf Α

Background: It remains uncertain whether vitamin D3 (vitD3) supplementation is beneficial for remission of Crohn's disease (CD). The influence of vitD3 supplementation on Infliximab (IFX) effectiveness was analyzed in Chinese CD patients.Methods: In this retrospective cohort study, moderate-to-severe CD patients, who were bio-naïve and prescribed with IFX treatment for at least 54 weeks, were recorded from January 2014 to December 2019. VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period. Disease activity was assessed using Harvey-Bradshaw Index (HBI). Serum cytokine profiles (IL-2, IL-4, IL-6, IL-10, TNF-α, and IFN-γ) were quantitatively analyzed in a subset of all patients at baseline and 54-week after intervention.Results: Among 73 enrolled patients, 37 took vitD3 regularly (D3-patients), the others (non-D3-patients) did not. At 54-week, the mean 25-hydroxyvitaminD level increased in D3-patients (20.33 vs. 15.07 ng/mL, P < 0.001). The clinical remission rate was higher in D3-patients compared to non-D3-patients (83.8 vs. 61.6%, P = 0.030). The decrease of HBI from baseline to 54-week was more in D3-patients than non-D3-patients (7.41 ± 3.0 vs. 6.28 ± 2.75, P = 0.023). Furthermore, vitD3 supplementation was independently related to the increase of remission rate at 54-week in D3-patients (β = −1.667, P = 0.015). The benefit of vitD3 supplementation was significant only in patients with deficient vitD3 (all P < 0.05), but not in non-deficient vitD3. A total of nine patients (four non-D3-patients and five D3-patients) were selected to determine serum cytokine profiles after 54-week IFX treatment. In non-D3-patients, the decreases of TNF-α and IL-6 at 54-week were more obvious than at baseline (P = 0.032, 0.022, respectively). In D3-patients, however, only IL-10 increased at 54-week compared with its baseline value (P = 0.037).Conclusions: VitD3 supplementation could improve IFX effectiveness in CD patients, especially for patients with vitD3 deficiency. This beneficial effect of vitD3 supplementation probably arose from the up-regulation of IL-10.Trial Registration: NCT04606017.

Short-Term Outcomes of Adalimumab for Patients with Crohn's Disease and Associated Prognostic Factors: A Multicenter Retrospective Cohort Study

2017 ◽  
Vol 152 (5) ◽  
pp. S408
Author(s):  
Masanao Nasuno ◽  
Hiroki Tanaka ◽  
Maki Miyakawa ◽  
Satoshi Motoya ◽  
Manabu Ishii ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Prognostic Factors ◽  
Crohn's Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Short Term

scholarly journals S3201 The Obesity Paradox in Crohn’s Disease: A Retrospective Cohort Study

2020 ◽  
Vol 115 (1) ◽  
pp. S1679-S1679
Author(s):  
Subash Ghimire ◽  
Amlish Gondal ◽  
Chandrakala Dadeboyina ◽  
Kriti Suwal ◽  
Swapna Talluri ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Obesity Paradox

scholarly journals Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis

2021 ◽  
Vol 8 (1) ◽  
pp. e000702
Author(s):  
Gala M Godoy Brewer ◽  
George Salem ◽  
Muhammad A Afzal ◽  
Berkeley N Limketkai ◽  
Zadid Haq ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Symptomatic Improvement ◽  
Symptomatic Remission

BackgroundPerianal Crohn’s disease (pCD) is a debilitating complication affecting up to 30% of Crohn’s disease (CD) population, leading to increased morbidity, mortality and decreased quality of life. Despite the growing armamentarium of medications for luminal CD, their efficacy in pCD remains poorly studied.AimTo determine the efficacy of ustekinumab, a biologic approved for luminal CD, in pCD through a retrospective cohort study and systematic review.MethodsA retrospective cohort study on patients with CD with active perianal fistulae treated with ustekinumab from September 2013 to August 2019 was performed to determine perianal fistula response and remission at 6 and 12 months after ustekinumab induction. A systematic review was performed to further establish rates of fistula response and remission with ustekinumab.ResultsAt 6 months, 48.1% (13/27) patients achieved fistula response with none achieving fistula remission on provider exam, and 59.3% (16/27) achieved patient-reported symptomatic improvement with 3.7% (1/27) achieving symptomatic remission. At 1 year, on provider exam, 55.6% (5/9) had fistula response with none achieving fistula remission, and 100% (9/9) had symptomatic improvement with 22.2% (2/9) achieving symptomatic remission. There were no major safety signals during 1-year follow-up. The systematic review of 25 studies found 44% (92/209) of patients with active perianal fistulas had a clinical response within 6 months of follow-up, and 53.9% (85/152) of patients with 12 months of follow-up achieved clinical response.ConclusionUstekinumab presents a safe and effective therapy for treatment of pCD. Prospective, randomised trials are needed to further elucidate long-term efficacy of ustekinumab for pCD.

Sign in / Sign up

Export Citation Format

Share Document